It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cancer immunotherapy has transformed traditional treatments, with immune checkpoint blockade being particularly prominent. However, immunotherapy has minimal benefit for patients in most types of cancer and is largely ineffective in some cancers (such as pancreatic cancer and glioma). A synergistic anti-tumor response may be produced through the combined application with traditional tumor treatment methods. Radiotherapy (RT) not only kills tumor cells but also triggers the pro-inflammatory molecules’ release and immune cell infiltration, which remodel the tumor microenvironment (TME). Therefore, the combination of RT and immunotherapy is expected to achieve improved efficacy. In this review, we summarize the effects of RT on cellular components of the TME, including T cell receptor repertoires, different T cell subsets, metabolism, tumor-associated macrophages and other myeloid cells (dendritic cells, myeloid-derived suppressor cells, neutrophils and eosinophils). Meanwhile, non-cellular components such as lactate and extracellular vesicles are also elaborated. In addition, we discuss the impact of different RT modalities on tumor immunity and issues related to the clinical practice of combination therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Sun, Zhenqiang 1
1 The First Affiliated Hospital of Zhengzhou University, Department of Colorectal Surgery, Zhengzhou, China (GRID:grid.412633.1); The First Affiliated Hospital of Zhengzhou University, Henan Institute of Interconnected Intelligent Health Management, Zhengzhou, China (GRID:grid.412633.1)
2 The First Affiliated Hospital of Zhengzhou University, Department of Breast Surgery, Zhengzhou, China (GRID:grid.412633.1)
3 The First Affiliated Hospital of Zhengzhou University, Department of Colorectal Surgery, Zhengzhou, China (GRID:grid.412633.1)
4 The First Affiliated Hospital of Zhengzhou University, Department of Oncology, Zhengzhou, China (GRID:grid.412633.1)
5 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Department of Internal Medicine, Zhengzhou, China (GRID:grid.414008.9) (ISNI:0000 0004 1799 4638)
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Department of Radiotherapy, Zhengzhou, China (GRID:grid.414008.9) (ISNI:0000 0004 1799 4638)




